Prema Cognition raises £550K to catch dementia earlier
What's the deal? Prema Cognition, a UK healthtech startup, has secured £550,000 in pre-seed funding to develop memory-precision tests aimed at detecting dementia earlier than current methods allow.
The company is building cognitive assessment tools designed to identify subtle memory decline before it progresses to full-blown dementia — a stage when intervention options are far more limited.
Why now? Dementia diagnoses are rising globally as populations age, yet early detection remains a stubborn clinical gap. Standard screening tools often catch cognitive decline only after significant damage has occurred. New treatments entering the market, including Lecanemab and Donanemab, work best when administered early — creating urgent demand for better diagnostic tools.
What could go wrong? Healthtech startups face a long, expensive path from prototype to clinical adoption. Prema Cognition will need to demonstrate that its tests are both scientifically validated and practically useful in real-world settings. Convincing healthcare systems to adopt new screening tools — particularly cash-strapped ones like the NHS — is notoriously difficult.
At £550,000, the runway is tight. The company will likely need to raise again soon to fund clinical validation and regulatory work.
The signal: Prema Cognition's modest pre-seed arrives at a pivotal moment for dementia diagnostics. With Lecanemab already approved and Donanemab progressing through regulatory review, the commercial case for early-detection tools is strengthening fast — pharma companies and health systems alike need ways to identify eligible patients before irreversible neurodegeneration sets in. The UK's ageing population and the NHS's push toward preventive care could give a homegrown diagnostic startup a meaningful first-mover advantage, provided it can clear the validation hurdle on a tight budget.
Read more: startupmag.co.uk
